BRIEF published on 01/08/2025 at 14:35, 1 year 10 months ago Santé Canada approuve le médicament biosimilaire FYB202/Otulfi® de Formycon Formycon Ustekinumab Coûts Des Soins De Santé Biosimilaire Approbation Du Canada
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 10 months ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 11 months ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
BRIEF published on 12/11/2024 at 16:31, 1 year 11 months ago Formycon AG maintient de solides perspectives de croissance dans un contexte de marché difficile Formycon AG Baisse Des Revenus Approbation De La FDA Biosimilaires Lancement De Stelara
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 11 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 11 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 11 months ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 11 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 11 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
BRIEF published on 12/05/2024 at 13:00, 1 year 11 months ago Formycon rejoint le SDAX de la Bourse allemande Stratégie De Marché SDAX Formycon Biosimilaires Bourse Allemande
Published on 11/20/2026 at 02:00, 10 hours 9 minutes ago PPX Mining Announces Completion of Debt Settlement
Published on 11/19/2026 at 23:30, 12 hours 39 minutes ago EQ Inc. Reports Third Quarter 2026 Financial Results
Published on 11/19/2026 at 23:00, 13 hours 9 minutes ago Redwood AI Reports Positive Interim Q-SAFE Findings Supporting Quantum-Assisted Chemical Safety Screening
Published on 11/19/2026 at 22:35, 13 hours 34 minutes ago Pampa Medina Drilling Intersects 102m of 1.0% Cu and 5.1g/t Ag from SPRD-21; 22m of 2.1% Cu and 10g/t Ag from SPRD-18; and 8m of 3.21% Cu and 27.5g/t Ag from SPRD-24
Published on 11/19/2026 at 22:25, 13 hours 44 minutes ago Kidoz Reports Record Nine-Month Revenue of US$9,900,750
Published on 11/20/2026 at 11:29, 39 minutes ago REPLOID implements 15-for-1 stock split and moves from auction to continuous trading
Published on 11/20/2026 at 11:05, 1 hour 3 minutes ago BIRKENSTOCK EXPANDS IN THE GREEK MARKET WITH THE OPENING OF TWO NEW RETAIL DESTINATIONS IN ATHENS
Published on 11/20/2026 at 10:59, 1 hour 10 minutes ago EQS-Adhoc: Revenue decreases by approximately 28.6% in the first half of the financial year // Positive revenue and earnings outlook for the 2026/2027 financial year remains unchanged
Published on 11/19/2026 at 19:00, 17 hours 9 minutes ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 19:00, 17 hours 9 minutes ago MR.BRICOLAGE : PERSPECTIVES POUR L'EXERCICE 2026
Published on 11/19/2026 at 08:30, 1 day 3 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing
Published on 11/19/2026 at 08:30, 1 day 3 hours ago Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité